A new design for registration trials in rheumatoid arthritis allowing secondary head-to-head comparisons with standard of care treatment including biologicals

Annals of the Rheumatic Diseases

Volumn 69, Issue 1, 2010, Pages 4-6

  Boers, Maarten ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

METHOTREXATE; TUMOR NECROSIS FACTOR INHIBITOR;

CLINICAL TRIAL; COMPARATIVE STUDY; DRUG EFFICACY; DRUG SAFETY; HUMAN; PATIENT CARE; PRIORITY JOURNAL; PROGNOSIS; RHEUMATOID ARTHRITIS; SHORT SURVEY; TREATMENT RESPONSE;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HUMANS; IMMUNOLOGIC FACTORS; METHOTREXATE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; TIME FACTORS; TREATMENT FAILURE; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 73449087363     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2009.110007     Document Type: Short Survey

References (14)

1. Pincus T, Sokka T, Chung CP, et al. Declines in number of tender and swollen joints in patients with rheumatoid arthritis seen in standard care in 1985 versus 2001: possible considerations for revision of inclusion criteria for clinical trials. Ann Rheum Dis 2006;65:878-83.
2. Sokka T, Kautiainen H, Toloza S, et al. QUEST-RA: quantitative clinical assessment of patients with rheumatoid arthritis seen in standard rheumatology care in 15 countries. Ann Rheum Dis 2007;66:1491-6.
3. Boers M. The time for 6-month placebo trials in rheumatoid arthritis has passed: a systematic comparison of 3- and 6-month response rates in trials of biologic agents. Ann Rheum Dis 2010;69:186-92.
4. Jones G, Gu JR, Lowenstein M, et al. The AMBITION Study: Superiority of tociluzumab (TCZ) vs methotrexate (MTX) monotherapy in patients with rheumatoid arthritis (RA). Arthritis Rheum 2008;57:S618.
5. Smolen J, Landewe RB, Mease P, et al. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Ann Rheum Dis 2009;68:797-804.
6. Kavanaugh A, McInnes I, Mease P, et al. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum 2009;60:976-86.
7. Bruynesteyn K, Landewe R, van der Linden S, et al. Radiography as primary outcome in rheumatoid arthritis: acceptable sample sizes for trials with 3 months' follow up. Ann Rheum Dis 2004;63:1413-8.
8. Boers M. Abatacept in rheumatoid arthritis: a new branch on the "biologics" tree. Ann Intern Med 2006;144:933-5.
9. Keystone EC, Genovese MC, Klareskog L, et al. Golimumab, a human antibody to tumour necrosis factor a given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD study. Ann Rheum Dis 2009;68:789-96.
10. Boers M. Add-on or step-up trials for new drug development in rheumatoid arthritis: a new standard? Arthritis Rheum 2003;48:1481-3.
11. Grigor C, Capell H, Stirling A, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 2004;364:263- 9.
12. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, et al. Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial. Ann Intern Med 2007;146:406-15.
13. Van Vollenhoven RF, Ernestam S, Geborek P, et al. In patients with early RA who failed initial MTX, the addition of anti-TNF yields better 1-year survival-on-therapy than the addition of conventional DMARDs. Ann Rheum Dis 2008;67(Suppl 2):333.
14. Honkanen VE, Siegel AF, Szalai JP, et al. A three-stage clinical trial design for rare disorders. Stat Med 2001;20:3009- 21.